Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free RPID Stock Alerts

Rapid Micro Biosystems (RPID) Financials

Rapid Micro Biosystems logo
$2.21 +0.14 (+6.76%)
Closing price 04:00 PM Eastern
Extended Trading
$2.24 +0.03 (+1.31%)
As of 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Rapid Micro Biosystems

Annual Income Statements for Rapid Micro Biosystems

This table shows Rapid Micro Biosystems' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -45 -78 -61 -52 -47 -47
Consolidated Net Income / (Loss)		 -37 -74 -61 -52 -47 -47
Net Income / (Loss) Continuing Operations		 -37 -74 -61 -52 -47 -47
Total Pre-Tax Income 		-37 -73 -61 -52 -47 -47
Total Operating Income		 -31 -47 -63 -57 -50 -47
Total Gross Profit		 -8.07 -7.74 -8.54 -5.49 -0.11 1.05
Total Revenue		 16 23 17 23 28 34
Operating Revenue		 16 23 17 23 28 34
Total Cost of Revenue		 24 31 26 28 28 33
Operating Cost of Revenue		 24 31 26 28 28 33
Total Operating Expenses		 22 39 55 51 50 48
Selling, General & Admin Expense		 9.98 18 27 25 22 23
Marketing Expense		 5.96 12 15 13 13 12
Research & Development Expense		 6.53 9.78 13 13 15 14
Total Other Income / (Expense), net		 -6.40 -26 1.84 4.13 3.05 0.31
Interest Expense		 6.36 5.71 -1.78 - 0.04 1.09
Interest & Investment Income		 - - - 4.21 3.20 1.51
Other Income / (Expense), net		 -0.05 -20 0.06 -0.08 -0.11 -0.11
Income Tax Expense		 0.13 0.09 -0.58 0.03 0.02 0.04
Basic Earnings per Share		 ($126.11) ($3.94) ($1.43) ($1.22) ($1.08) ($1.05)
Weighted Average Basic Shares Outstanding		 358.58K 19.78M 42.45M 43.02M 43.58M 44.68M
Diluted Earnings per Share		 ($126.11) ($3.94) ($1.43) ($1.22) ($1.08) ($1.05)
Weighted Average Diluted Shares Outstanding		 358.58K 19.78M 42.45M 43.02M 43.58M 44.68M
Weighted Average Basic & Diluted Shares Outstanding		 - 41.94M 42.19M 42.50M 43.24M 45.46M

Quarterly Income Statements for Rapid Micro Biosystems

This table shows Rapid Micro Biosystems' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -13 -11 -13 -13 -11 -9.67 -11 -12 -12 -12 -14
Consolidated Net Income / (Loss)		 -13 -11 -13 -13 -11 -9.67 -11 -12 -12 -12 -14
Net Income / (Loss) Continuing Operations		 -13 -11 -13 -13 -11 -9.67 -11 -12 -12 -12 -14
Total Pre-Tax Income 		-13 -11 -13 -13 -11 -9.68 -11 -12 -11 -12 -14
Total Operating Income		 -14 -12 -14 -13 -12 -10 -12 -12 -11 -12 -14
Total Gross Profit		 -1.63 -0.17 -1.52 -0.19 0.62 0.98 0.40 0.28 0.70 -0.33 0.37
Total Revenue		 6.15 6.34 5.61 6.62 7.60 8.22 7.21 7.26 7.84 11 8.00
Operating Revenue		 6.15 6.34 5.61 6.62 7.60 8.22 7.21 7.26 7.84 11 8.00
Total Cost of Revenue		 7.78 6.51 7.13 6.81 6.98 7.24 6.80 6.99 7.14 12 7.63
Operating Cost of Revenue		 7.78 6.51 7.13 6.81 6.98 7.24 6.80 6.99 7.14 12 7.63
Total Operating Expenses		 13 12 13 13 13 11 12 12 12 12 14
Selling, General & Admin Expense		 6.20 5.54 5.63 5.82 5.68 4.83 5.69 6.08 5.64 5.34 7.44
Marketing Expense		 3.50 3.16 3.28 3.63 3.38 2.98 2.75 3.11 2.90 3.32 3.42
Research & Development Expense		 3.12 3.32 3.84 3.74 3.61 3.40 3.62 3.23 3.53 3.22 3.36
Total Other Income / (Expense), net		 1.07 1.02 0.95 0.82 0.73 0.55 0.41 0.30 -0.13 -0.27 -0.42
Interest Expense		 - - - - 0.01 - 0.01 - 0.39 - 0.64
Interest & Investment Income		 1.09 - 0.98 0.84 0.78 - 0.47 0.35 0.35 0.35 0.26
Other Income / (Expense), net		 -0.03 -0.02 -0.03 -0.02 -0.04 -0.02 -0.05 -0.05 -0.08 0.08 -0.03
Income Tax Expense		 0.01 0.01 0.00 0.02 0.01 -0.01 0.01 0.01 0.01 0.01 0.01
Basic Earnings per Share		 ($0.31) ($0.26) ($0.31) ($0.29) ($0.26) ($0.22) ($0.26) ($0.27) ($0.26) ($0.26) ($0.31)
Weighted Average Basic Shares Outstanding		 43.08M 43.02M 43.25M 43.62M 43.67M 43.58M 43.99M 44.65M 44.96M 44.68M 45.43M
Diluted Earnings per Share		 ($0.31) ($0.26) ($0.31) ($0.29) ($0.26) ($0.22) ($0.26) ($0.27) ($0.26) ($0.26) ($0.31)
Weighted Average Diluted Shares Outstanding		 43.08M 43.02M 43.25M 43.62M 43.67M 43.58M 43.99M 44.65M 44.96M 44.68M 45.43M
Weighted Average Basic & Diluted Shares Outstanding		 42.40M 42.50M 42.86M 42.91M 43.03M 43.24M 43.83M 44.21M 44.32M 45.46M 46.17M

Annual Cash Flow Statements for Rapid Micro Biosystems

This table details how cash moves in and out of Rapid Micro Biosystems' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 18 148 -151 -2.78 -7.29 3.04
Net Cash From Operating Activities		 -31 -55 -59 -45 -44 -31
Net Cash From Continuing Operating Activities		 -31 -55 -59 -45 -44 -31
Net Income / (Loss) Continuing Operations		 -37 -74 -61 -52 -47 -47
Consolidated Net Income / (Loss)		 -37 -74 -61 -52 -47 -47
Depreciation Expense		 1.51 1.53 2.84 3.11 3.36 3.25
Non-Cash Adjustments To Reconcile Net Income		 5.67 25 4.75 3.73 4.15 6.75
Changes in Operating Assets and Liabilities, net		 -1.10 -8.00 -5.33 0.56 -4.77 6.06
Net Cash From Investing Activities		 -16 -13 -93 42 37 14
Net Cash From Continuing Investing Activities		 -16 -13 -93 42 37 14
Purchase of Property, Plant & Equipment		 -0.69 -3.22 -6.74 -1.85 -1.37 -0.85
Purchase of Investments		 -25 -25 -179 -62 -35 -27
Sale and/or Maturity of Investments		 10 15 93 106 73 42
Net Cash From Financing Activities		 64 217 0.69 0.15 0.20 20
Net Cash From Continuing Financing Activities		 64 217 0.69 0.15 0.20 20
Repayment of Debt		 -20 -28 - - 0.00 -0.88
Issuance of Debt		 35 - - - 0.00 20
Issuance of Common Equity		 0.00 165 0.73 0.19 0.24 1.10
Other Financing Activities, net		 0.07 0.54 -0.03 -0.04 -0.04 -0.45
Cash Interest Paid		 1.98 2.59 0.04 0.04 0.04 0.77

Quarterly Cash Flow Statements for Rapid Micro Biosystems

This table details how cash moves in and out of Rapid Micro Biosystems' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.89 0.50 -1.85 15 -15 -5.05 2.00 -0.65 0.61 1.08 -6.22
Net Cash From Operating Activities		 -9.71 -9.50 -16 -10 -8.60 -9.91 -9.07 -9.70 -9.05 -3.25 -15
Net Cash From Continuing Operating Activities		 -9.71 -9.50 -16 -10 -8.60 -9.91 -9.07 -9.70 -9.05 -3.25 -15
Net Income / (Loss) Continuing Operations		 -13 -11 -13 -13 -11 -9.67 -11 -12 -12 -12 -14
Consolidated Net Income / (Loss)		 -13 -11 -13 -13 -11 -9.67 -11 -12 -12 -12 -14
Depreciation Expense		 0.78 0.79 0.81 0.83 0.86 0.87 0.85 0.81 0.80 0.79 0.71
Amortization Expense		 - - - - - - 0.00 - - - 0.09
Non-Cash Adjustments To Reconcile Net Income		 1.01 0.81 0.98 1.11 1.09 0.96 1.64 1.85 1.68 1.57 1.65
Changes in Operating Assets and Liabilities, net		 1.90 0.08 -3.99 0.53 0.77 -2.08 -0.29 -0.51 -0.03 6.89 -3.22
Net Cash From Investing Activities		 4.77 10 14 25 -6.54 4.86 11 9.34 -9.58 3.89 8.60
Net Cash From Continuing Investing Activities		 4.77 10 14 25 -6.54 4.86 11 9.34 -9.58 3.89 8.60
Purchase of Property, Plant & Equipment		 -0.45 -0.42 -0.59 -0.46 -0.22 -0.10 -0.32 -0.37 -0.07 -0.09 -0.39
Purchase of Investments		 -24 -12 -4.38 0.01 -25 -5.54 0.00 -2.29 -21 -4.02 -3.02
Sale and/or Maturity of Investments		 30 22 18 25 19 11 11 12 11 8.00 12
Net Cash From Financing Activities		 0.05 -0.01 0.16 -0.01 0.06 -0.01 0.38 -0.30 19 0.44 0.25
Net Cash From Continuing Financing Activities		 0.05 -0.01 0.16 -0.01 0.06 -0.01 0.38 -0.30 19 0.44 0.25
Issuance of Common Equity		 0.06 -0.00 0.17 - 0.07 - 0.39 0.13 0.13 0.45 0.26
Other Financing Activities, net		 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.43 -0.01 -0.01 -0.01
Cash Interest Paid		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.16 0.58 0.56

Annual Balance Sheets for Rapid Micro Biosystems

This table presents Rapid Micro Biosystems' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 70 241 191 143 98 75
Total Current Assets		 62 218 139 120 81 61
Cash & Equivalents		 30 178 27 24 17 20
Short-Term Investments		 15 15 82 68 34 18
Accounts Receivable		 4.99 5.01 5.37 5.53 7.52 3.13
Inventories, net		 8.97 16 21 20 20 18
Prepaid Expenses		 3.12 3.95 3.37 2.87 2.47 2.15
Plant, Property, & Equipment, net		 7.05 11 14 13 11 8.97
Total Noncurrent Assets		 0.10 12 38 10 6.06 4.71
Other Noncurrent Operating Assets		 0.10 1.78 8.47 7.29 6.06 4.71
Total Liabilities & Shareholders' Equity		 70 241 191 143 98 75
Total Liabilities		 45 20 26 25 23 42
Total Current Liabilities		 16 18 19 19 18 18
Accounts Payable		 4.47 3.94 5.43 1.97 2.54 4.14
Accrued Expenses		 6.65 11 8.15 9.91 7.22 8.32
Current Deferred Revenue		 4.42 3.31 4.71 5.97 6.60 4.73
Other Current Liabilities		 - 0.00 0.77 1.13 1.21 1.30
Total Noncurrent Liabilities		 30 2.02 7.43 6.48 5.25 23
Long-Term Debt		 25 - - - 0.00 19
Other Noncurrent Operating Liabilities		 4.12 1.21 7.43 6.48 0.30 4.26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -127 221 164 118 75 33
Total Preferred & Common Equity		 -127 221 164 118 75 33
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -127 221 164 118 75 33
Common Stock		 115 536 541 546 550 556
Retained Earnings		 -242 -315 -376 -428 -475 -522
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.02 -1.11 -0.10 0.04 0.01

Quarterly Balance Sheets for Rapid Micro Biosystems

This table presents Rapid Micro Biosystems' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 150 128 117 106 85 76 84 62
Total Current Assets		 115 108 98 88 69 60 70 49
Cash & Equivalents		 24 22 37 22 19 18 19 14
Short-Term Investments		 66 57 32 39 23 13 22 9.13
Accounts Receivable		 3.91 4.92 5.01 3.74 4.52 6.05 5.43 6.37
Inventories, net		 20 20 21 21 21 21 21 17
Prepaid Expenses		 1.56 3.29 2.37 2.11 2.27 2.28 2.21 2.46
Plant, Property, & Equipment, net		 13 13 12 12 11 10 9.58 8.77
Total Noncurrent Assets		 22 6.96 6.62 6.35 5.69 5.24 4.87 4.37
Other Noncurrent Operating Assets		 7.63 6.96 6.62 6.35 5.69 5.24 4.87 4.37
Total Liabilities & Shareholders' Equity		 150 128 117 106 85 76 84 62
Total Liabilities		 22 22 22 21 20 21 40 42
Total Current Liabilities		 16 16 17 16 15 16 17 19
Accounts Payable		 3.27 1.16 2.18 2.33 2.64 3.33 3.59 4.67
Accrued Expenses		 6.95 7.05 7.82 7.04 5.03 5.68 6.61 6.50
Current Deferred Revenue		 4.56 6.23 5.43 5.36 6.09 6.14 5.07 6.63
Other Current Liabilities		 0.84 1.15 1.17 1.19 1.24 1.26 1.28 1.32
Total Noncurrent Liabilities		 6.76 6.19 5.90 5.55 4.95 4.64 24 23
Long-Term Debt		 - - - - - - 19 19
Other Noncurrent Operating Liabilities		 6.76 6.19 5.90 5.55 4.95 0.31 0.70 3.79
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 128 106 95 84 65 55 44 20
Total Preferred & Common Equity		 128 106 95 84 65 55 44 20
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 128 106 95 84 65 54 44 20
Common Stock		 545 548 549 550 552 553 554 557
Retained Earnings		 -417 -442 -454 -466 -487 -498 -510 -537
Accumulated Other Comprehensive Income / (Loss)		 -0.45 -0.08 -0.03 0.08 0.01 -0.00 0.01 -0.00

Annual Metrics And Ratios for Rapid Micro Biosystems

This table displays calculated financial ratios and metrics derived from Rapid Micro Biosystems' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 41,352,523.00 41,994,285.00 42,398,905.00 - 44,322,555.00
DEI Adjusted Shares Outstanding		 0.00 41,352,523.00 41,994,285.00 42,398,905.00 - 44,322,555.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.89 -1.45 -1.24 - -1.06
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 44.50% -26.25% 31.44% 24.57% 19.74%
EBITDA Growth		 0.00% -127.65% 8.87% 11.24% 12.84% 5.18%
EBIT Growth		 0.00% -121.42% 6.74% 10.31% 11.68% 5.05%
NOPAT Growth		 0.00% -54.66% -33.85% 10.53% 11.75% 5.06%
Net Income Growth		 0.00% -98.30% 17.30% 13.71% 10.63% -0.50%
EPS Growth		 0.00% 96.88% 63.71% 14.69% 11.48% 2.78%
Operating Cash Flow Growth		 0.00% -77.33% -6.52% 23.00% 2.06% 29.65%
Free Cash Flow Firm Growth		 0.00% 0.00% -12.30% 29.69% 0.95% 58.03%
Invested Capital Growth		 0.00% 354.04% 46.89% -10.52% 6.93% -53.30%
Revenue Q/Q Growth		 0.00% 0.00% -4.64% 9.55% 7.19% 10.04%
EBITDA Q/Q Growth		 0.00% 0.00% -3.93% 8.54% 4.17% -4.63%
EBIT Q/Q Growth		 0.00% 0.00% -4.45% 8.21% 3.76% -4.12%
NOPAT Q/Q Growth		 0.00% 0.00% -4.47% 8.23% 3.78% -4.36%
Net Income Q/Q Growth		 0.00% 0.00% -3.12% 9.14% 3.11% -6.39%
EPS Q/Q Growth		 0.00% 0.00% -102.67% 9.63% 3.57% -3.96%
Operating Cash Flow Q/Q Growth		 0.00% -16.33% 2.06% 4.57% -0.94% 17.66%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 2.96% -1.28% 49.03%
Invested Capital Q/Q Growth		 0.00% 0.00% -10.99% -3.17% 4.58% -46.70%
Profitability Metrics		 - - - - - -
Gross Margin		 -50.20% -33.32% -49.85% -24.36% -0.39% 3.12%
EBITDA Margin		 -180.87% -284.93% -352.09% -237.76% -166.37% -131.75%
Operating Margin		 -189.96% -203.31% -368.99% -251.18% -177.96% -141.10%
EBIT Margin		 -190.25% -291.52% -368.65% -251.55% -178.36% -141.43%
Profit (Net Income) Margin		 -230.63% -316.48% -354.91% -232.99% -167.16% -140.30%
Tax Burden Percent		 100.36% 100.12% 99.06% 100.06% 100.05% 100.09%
Interest Burden Percent		 120.78% 108.43% 97.18% 92.57% 93.68% 99.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -554.12% -309.36% -204.65% -162.42% -146.68% -152.93%
ROIC Less NNEP Spread (ROIC-NNEP)		 -479.22% -273.30% -194.97% -151.39% -130.28% -110.12%
Return on Net Nonoperating Assets (RNNOA)		 404.73% 249.53% 173.07% 125.23% 98.18% 66.11%
Return on Equity (ROE)		 -149.39% -59.82% -31.58% -37.19% -48.50% -86.82%
Cash Return on Invested Capital (CROIC)		 0.00% -437.16% -242.63% -151.32% -153.38% -80.27%
Operating Return on Assets (OROA)		 -43.70% -43.53% -29.25% -33.91% -41.41% -54.91%
Return on Assets (ROA)		 -52.97% -47.26% -28.16% -31.41% -38.81% -54.47%
Return on Common Equity (ROCE)		 764.43% -22.87% -31.58% -37.19% -48.50% -86.51%
Return on Equity Simple (ROE_SIMPLE)		 29.19% -33.27% -37.04% -44.47% -62.23% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -33 -44 -40 -35 -33
NOPAT Margin		 -132.97% -142.31% -258.29% -175.83% -124.57% -98.77%
Net Nonoperating Expense Percent (NNEP)		 -74.90% -36.06% -9.68% -11.03% -16.40% -42.81%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -33.56% -46.37% -63.66%
Cost of Revenue to Revenue		 150.20% 133.32% 149.85% 124.36% 100.39% 96.88%
SG&A Expenses to Revenue		 62.05% 77.03% 156.53% 110.73% 78.24% 67.75%
R&D to Revenue		 40.62% 42.10% 75.09% 56.93% 52.04% 40.50%
Operating Expenses to Revenue		 139.76% 169.99% 319.14% 226.82% 177.57% 144.22%
Earnings before Interest and Taxes (EBIT)		 -31 -68 -63 -57 -50 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -66 -60 -54 -47 -44
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 1.99 0.29 0.27 0.51 3.87
Price to Tangible Book Value (P/TBV)		 0.00 1.99 0.29 0.27 0.51 3.87
Price to Revenue (P/Rev)		 8.21 18.94 2.77 1.39 1.38 3.83
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 68.31 13.50 0.00 0.00 0.00 7.90
Enterprise Value to Revenue (EV/Rev)		 16.39 10.18 0.00 0.00 0.00 3.25
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 1.00 0.00 0.00 0.00 0.00 0.57
Long-Term Debt to Equity		 1.00 0.00 0.00 0.00 0.00 0.57
Financial Leverage		 -0.84 -0.91 -0.89 -0.83 -0.75 -0.60
Leverage Ratio		 2.82 1.27 1.12 1.18 1.25 1.59
Compound Leverage Factor		 3.41 1.37 1.09 1.10 1.17 1.58
Debt to Total Capital		 49.99% 0.00% 0.00% 0.00% 0.00% 36.27%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 49.99% 0.00% 0.00% 0.00% 0.00% 36.27%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 305.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -255.91% 100.00% 100.00% 100.00% 100.00% 63.73%
Debt to EBITDA		 -0.85 0.00 0.00 0.00 0.00 -0.43
Net Debt to EBITDA		 0.70 0.00 0.00 0.00 0.00 0.44
Long-Term Debt to EBITDA		 -0.85 0.00 0.00 0.00 0.00 -0.43
Debt to NOPAT		 -1.16 0.00 0.00 0.00 0.00 -0.57
Net Debt to NOPAT		 0.95 0.00 0.00 0.00 0.00 0.58
Long-Term Debt to NOPAT		 -1.16 0.00 0.00 0.00 0.00 -0.57
Altman Z-Score		 -3.49 11.41 -1.94 -3.74 -6.38 -8.88
Noncontrolling Interest Sharing Ratio		 611.71% 61.77% 0.00% 0.00% 0.00% 0.35%
Liquidity Ratios		 - - - - - -
Current Ratio		 4.00 12.01 7.27 6.34 4.61 3.31
Quick Ratio		 3.22 10.93 5.99 5.14 3.32 2.24
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -47 -52 -37 -37 -17
Operating Cash Flow to CapEx		 -4,492.17% -1,719.24% -868.65% -2,443.41% -3,234.65% -3,654.35%
Free Cash Flow to Firm to Interest Expense		 0.00 -8.19 0.00 0.00 0.00 -15.97
Operating Cash Flow to Interest Expense		 -4.88 -9.63 0.00 0.00 0.00 -28.50
Operating Cash Flow Less CapEx to Interest Expense		 -4.98 -10.19 0.00 0.00 0.00 -29.28
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.23 0.15 0.08 0.13 0.23 0.39
Accounts Receivable Turnover		 3.22 4.65 3.30 4.13 4.30 6.31
Inventory Turnover		 2.69 2.51 1.39 1.36 1.40 1.72
Fixed Asset Turnover		 2.28 2.53 1.36 1.69 2.34 3.33
Accounts Payable Turnover		 5.40 7.36 5.48 7.57 12.49 9.75
Days Sales Outstanding (DSO)		 113.24 78.50 110.50 88.34 84.91 57.88
Days Inventory Outstanding (DIO)		 135.51 145.16 262.01 268.16 260.28 211.96
Days Payable Outstanding (DPO)		 67.53 49.57 66.62 48.23 29.22 37.43
Cash Conversion Cycle (CCC)		 181.22 174.10 305.89 308.27 315.97 232.42
Capital & Investment Metrics		 - - - - - -
Invested Capital		 3.86 18 26 23 25 14
Invested Capital Turnover		 4.17 2.17 0.79 0.92 1.18 1.55
Increase / (Decrease) in Invested Capital		 0.00 14 8.21 -2.71 1.60 -16
Enterprise Value (EV)		 264 237 -91 -64 -12 109
Market Capitalization		 132 440 47 31 39 129
Book Value per Share		 ($354.19) $5.34 $3.91 $2.78 $1.75 $0.75
Tangible Book Value per Share		 ($354.19) $5.34 $3.91 $2.78 $1.75 $0.75
Total Capital		 50 221 164 118 75 52
Total Debt		 25 0.00 0.00 0.00 0.00 19
Total Long-Term Debt		 25 0.00 0.00 0.00 0.00 19
Net Debt		 -20 -203 -138 -95 -51 -19
Capital Expenditures (CapEx)		 0.69 3.20 6.74 1.85 1.37 0.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.53 6.46 11 9.38 13 4.39
Debt-free Net Working Capital (DFNWC)		 47 200 120 101 63 43
Net Working Capital (NWC)		 47 200 120 101 63 43
Net Nonoperating Expense (NNE)		 16 40 17 13 12 14
Net Nonoperating Obligations (NNO)		 -21 -203 -138 -95 -51 -19
Total Depreciation and Amortization (D&A)		 1.51 1.53 2.84 3.11 3.36 3.25
Debt-free, Cash-free Net Working Capital to Revenue		 9.50% 27.81% 63.49% 41.64% 44.99% 13.06%
Debt-free Net Working Capital to Revenue		 289.89% 860.70% 697.64% 450.42% 225.85% 127.08%
Net Working Capital to Revenue		 289.89% 860.70% 697.64% 450.42% 225.85% 127.08%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.94) ($1.43) ($1.22) ($1.08) ($1.05)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 19.78M 42.45M 43.02M 43.58M 44.68M
Adjusted Diluted Earnings per Share		 $0.00 ($3.94) ($1.43) ($1.22) ($1.08) ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 19.78M 42.45M 43.02M 43.58M 44.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 41.94M 42.19M 42.50M 43.24M 45.46M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -33 -44 -40 -35 -33
Normalized NOPAT Margin		 -132.97% -142.31% -258.29% -175.83% -124.57% -98.77%
Pre Tax Income Margin		 -229.79% -316.09% -358.27% -232.85% -167.08% -140.18%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -4.81 -11.86 0.00 0.00 0.00 -43.58
NOPAT to Interest Expense		 -3.36 -5.79 0.00 0.00 0.00 -30.44
EBIT Less CapEx to Interest Expense		 -4.92 -12.43 0.00 0.00 0.00 -44.36
NOPAT Less CapEx to Interest Expense		 -3.47 -6.35 0.00 0.00 0.00 -31.22
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Rapid Micro Biosystems

This table displays calculated financial ratios and metrics derived from Rapid Micro Biosystems' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 42,332,006.00 42,398,905.00 42,497,413.00 42,861,816.00 42,914,151.00 - 43,236,690.00 43,831,701.00 44,210,328.00 44,322,555.00 45,462,993.00
DEI Adjusted Shares Outstanding		 42,332,006.00 42,398,905.00 42,497,413.00 42,861,816.00 42,914,151.00 - 43,236,690.00 43,831,701.00 44,210,328.00 44,322,555.00 45,462,993.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.32 -0.26 -0.31 -0.29 -0.26 - -0.26 -0.27 -0.26 -0.28 -0.31
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 29.67% 44.88% 11.44% 32.31% 23.74% 29.68% 28.41% 9.73% 3.08% 37.28% 11.06%
EBITDA Growth		 15.33% 30.47% 4.45% 12.15% 18.07% 17.79% 19.51% 9.43% 5.10% -20.89% -20.52%
EBIT Growth		 14.38% 29.33% 3.90% 11.15% 16.56% 16.02% 18.12% 8.98% 5.19% -18.35% -18.57%
NOPAT Growth		 14.43% 29.39% 4.03% 11.13% 16.68% 16.07% 18.30% 9.19% 5.54% -19.38% -18.79%
Net Income Growth		 18.04% 32.07% 4.07% 10.26% 15.45% 13.48% 15.46% 5.72% -1.61% -29.29% -26.74%
EPS Growth		 18.42% 33.33% 3.13% 12.12% 16.13% 15.38% 16.13% 6.90% 0.00% -18.18% -19.23%
Operating Cash Flow Growth		 35.73% 18.52% 6.96% -10.11% 11.41% -4.34% 41.61% 4.14% -5.24% 67.24% -66.11%
Free Cash Flow Firm Growth		 81.48% 71.30% 65.74% 6.03% -64.32% -50.29% 8.63% -32.26% -26.17% 152.62% 57.37%
Invested Capital Growth		 -17.75% -10.52% -12.83% -4.22% -1.00% 6.93% -9.79% 9.58% 10.08% -53.30% -30.73%
Revenue Q/Q Growth		 22.85% 3.12% -11.46% 17.95% 14.90% 8.07% -12.33% 0.79% 7.93% 43.94% -29.07%
EBITDA Q/Q Growth		 4.32% 16.67% -18.27% 6.84% 10.77% 16.38% -15.80% -4.71% 6.50% -6.52% -15.44%
EBIT Q/Q Growth		 4.03% 15.68% -17.18% 6.30% 9.87% 15.14% -14.24% -4.06% 6.12% -5.94% -14.45%
NOPAT Q/Q Growth		 4.02% 15.65% -17.11% 6.27% 10.01% 15.03% -14.00% -4.18% 6.39% -7.38% -13.44%
Net Income Q/Q Growth		 4.45% 16.58% -19.24% 5.58% 9.98% 14.63% -16.52% -5.28% 2.98% -8.62% -14.23%
EPS Q/Q Growth		 6.06% 16.13% -19.23% 6.45% 10.34% 15.38% -18.18% -3.85% 3.70% 0.00% -19.23%
Operating Cash Flow Q/Q Growth		 -5.64% 2.17% -63.47% 34.82% 15.01% -15.22% 8.52% -7.01% 6.69% 64.14% -363.89%
Free Cash Flow Firm Q/Q Growth		 43.27% -16.88% -4.76% -35.27% 0.79% -6.90% 59.32% -95.79% 5.36% 169.82% -132.95%
Invested Capital Q/Q Growth		 -9.62% -3.17% 14.69% -4.57% -6.58% 4.58% -19.45% 15.92% -6.16% -46.70% 19.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -26.54% -2.71% -27.14% -2.86% 8.18% 11.94% 5.61% 3.79% 8.88% -2.91% 4.64%
EBITDA Margin		 -222.85% -180.07% -240.53% -189.98% -147.54% -114.15% -150.77% -156.80% -135.84% -100.52% -163.61%
Operating Margin		 -235.13% -192.33% -254.38% -202.15% -158.32% -124.47% -161.85% -167.28% -145.09% -108.23% -173.11%
EBIT Margin		 -235.56% -192.60% -254.89% -202.49% -158.84% -124.73% -162.53% -167.97% -146.10% -107.53% -173.51%
Profit (Net Income) Margin		 -217.93% -176.30% -237.43% -190.06% -148.91% -117.62% -156.32% -163.29% -146.78% -110.77% -178.39%
Tax Burden Percent		 100.07% 100.07% 100.02% 100.12% 100.11% 99.91% 100.06% 100.09% 100.07% 100.11% 100.06%
Interest Burden Percent		 92.45% 91.47% 93.13% 93.75% 93.64% 94.39% 96.12% 97.12% 100.40% 102.90% 102.76%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -128.44% -124.36% -145.05% -135.77% -122.59% -102.60% -133.73% -134.31% -125.37% -117.30% -206.65%
ROIC Less NNEP Spread (ROIC-NNEP)		 -125.86% -122.10% -141.75% -132.26% -119.07% -99.16% -128.62% -127.35% -116.42% -105.18% -186.56%
Return on Net Nonoperating Assets (RNNOA)		 104.24% 101.00% 110.64% 103.17% 92.52% 74.72% 90.93% 82.25% 71.69% 63.15% 98.97%
Return on Equity (ROE)		 -24.19% -23.36% -34.41% -32.60% -30.07% -27.87% -42.80% -52.06% -53.68% -54.16% -107.68%
Cash Return on Invested Capital (CROIC)		 -144.31% -151.32% -124.46% -143.25% -152.49% -153.38% -121.56% -131.29% -138.15% -80.27% -135.85%
Operating Return on Assets (OROA)		 -27.51% -25.96% -39.11% -35.99% -32.47% -28.96% -45.21% -52.81% -46.88% -41.75% -80.73%
Return on Assets (ROA)		 -25.45% -23.77% -36.43% -33.78% -30.44% -27.31% -43.48% -51.34% -47.10% -43.01% -83.00%
Return on Common Equity (ROCE)		 -24.19% -23.36% -34.41% -32.60% -30.07% -27.87% -42.80% -51.93% -53.51% -53.97% -107.68%
Return on Equity Simple (ROE_SIMPLE)		 -45.19% 0.00% -48.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -10 -8.53 -9.99 -9.36 -8.43 -7.16 -8.16 -8.50 -7.96 -8.55 -9.70
NOPAT Margin		 -164.59% -134.63% -178.06% -141.50% -110.83% -87.13% -113.29% -117.10% -101.56% -75.76% -121.17%
Net Nonoperating Expense Percent (NNEP)		 -2.58% -2.26% -3.30% -3.52% -3.51% -3.44% -5.12% -6.97% -8.95% -12.12% -20.10%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.23% -9.43% -9.90% -9.99% -9.50% -12.46% -14.45% -11.85% -16.40% -24.58%
Cost of Revenue to Revenue		 126.54% 102.71% 127.14% 102.86% 91.82% 88.06% 94.39% 96.21% 91.12% 102.91% 95.36%
SG&A Expenses to Revenue		 100.96% 87.38% 100.29% 87.91% 74.64% 58.72% 78.97% 83.71% 72.01% 47.34% 93.00%
R&D to Revenue		 50.71% 52.36% 68.47% 56.57% 47.46% 41.40% 50.30% 44.48% 45.02% 28.54% 41.98%
Operating Expenses to Revenue		 208.59% 189.62% 227.23% 199.29% 166.50% 136.41% 167.45% 171.07% 153.97% 105.33% 177.74%
Earnings before Interest and Taxes (EBIT)		 -14 -12 -14 -13 -12 -10 -12 -12 -11 -12 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -14 -11 -13 -13 -11 -9.38 -11 -11 -11 -11 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.36 0.27 0.39 0.30 0.45 0.51 1.74 2.79 3.36 3.87 5.06
Price to Tangible Book Value (P/TBV)		 0.36 0.27 0.39 0.30 0.45 0.51 1.74 2.79 3.36 3.87 5.06
Price to Revenue (P/Rev)		 2.22 1.39 1.78 1.14 1.46 1.38 3.85 4.99 4.84 3.83 3.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 3.04 4.50 4.99 7.90 6.02
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 2.44 4.10 4.23 3.25 2.89
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.52 0.57 0.93
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.52 0.57 0.93
Financial Leverage		 -0.83 -0.83 -0.78 -0.78 -0.78 -0.75 -0.71 -0.65 -0.62 -0.60 -0.53
Leverage Ratio		 1.15 1.18 1.17 1.19 1.21 1.25 1.24 1.29 1.48 1.59 1.72
Compound Leverage Factor		 1.06 1.08 1.08 1.11 1.13 1.18 1.20 1.25 1.48 1.64 1.77
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.35% 33.99% 36.27% 48.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.35% 33.99% 36.27% 48.30%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 91.98% 65.42% 63.73% 51.70%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.10 -0.54 -0.43 -0.41
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.63 0.44 0.44 0.08
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.10 -0.54 -0.43 -0.41
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.13 -0.72 -0.57 -0.55
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.84 0.58 0.58 0.11
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.13 -0.72 -0.57 -0.55
Altman Z-Score		 -2.05 -2.72 -3.03 -4.01 -4.40 -5.04 -3.88 -4.36 -5.57 -7.32 -10.18
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.26% 0.31% 0.35% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.37 6.34 6.93 5.92 5.52 4.61 4.61 3.67 4.23 3.31 2.57
Quick Ratio		 5.97 5.14 5.41 4.48 4.06 3.32 3.08 2.27 2.82 2.24 1.53
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.98 -5.83 -6.10 -8.26 -8.19 -8.76 -5.58 -11 -10 7.21 -2.38
Operating Cash Flow to CapEx		 -2,143.05% -2,272.01% -2,653.85% -2,204.58% -3,856.50% -10,111.22% -2,841.69% -2,650.27% -12,398.63% -3,528.26% -3,821.83%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -744.57 0.00 -464.73 0.00 -26.29 0.00 -3.72
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -781.82 0.00 -755.42 0.00 -23.03 0.00 -23.56
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -802.09 0.00 -782.00 0.00 -23.22 0.00 -24.18
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.13 0.15 0.18 0.20 0.23 0.28 0.31 0.32 0.39 0.47
Accounts Receivable Turnover		 4.80 4.13 4.43 5.84 6.84 4.30 6.28 5.48 6.66 6.31 6.32
Inventory Turnover		 1.38 1.36 1.37 1.33 1.32 1.40 1.35 1.33 1.33 1.72 1.75
Fixed Asset Turnover		 1.58 1.69 1.77 1.95 2.14 2.34 2.56 2.70 2.89 3.33 3.56
Accounts Payable Turnover		 8.20 7.57 23.10 15.93 9.80 12.49 14.65 10.16 9.51 9.75 9.14
Days Sales Outstanding (DSO)		 76.04 88.34 82.43 62.53 53.33 84.91 58.13 66.63 54.83 57.88 57.79
Days Inventory Outstanding (DIO)		 263.57 268.16 266.61 273.94 275.73 260.28 269.81 273.61 274.21 211.96 208.75
Days Payable Outstanding (DPO)		 44.49 48.23 15.80 22.91 37.26 29.22 24.92 35.93 38.36 37.43 39.95
Cash Conversion Cycle (CCC)		 295.12 308.27 333.24 313.57 291.80 315.97 303.02 304.31 290.67 232.42 226.59
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 24 23 26 25 24 25 24 28 26 14 17
Invested Capital Turnover		 0.78 0.92 0.81 0.96 1.11 1.18 1.18 1.15 1.23 1.55 1.71
Increase / (Decrease) in Invested Capital		 -5.13 -2.71 -3.89 -1.11 -0.24 1.60 -2.59 2.42 2.37 -16 -7.32
Enterprise Value (EV)		 -58 -64 -38 -41 -23 -12 72 124 129 109 99
Market Capitalization		 46 31 41 28 38 39 114 151 148 129 103
Book Value per Share		 $3.02 $2.78 $2.49 $2.21 $1.97 $1.75 $1.51 $1.24 $0.99 $0.75 $0.45
Tangible Book Value per Share		 $3.02 $2.78 $2.49 $2.21 $1.97 $1.75 $1.51 $1.24 $0.99 $0.75 $0.45
Total Capital		 128 118 106 95 84 75 65 59 67 52 39
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.32 23 19 19
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.32 23 19 19
Net Debt		 -104 -95 -80 -69 -61 -51 -42 -27 -18 -19 -3.90
Capital Expenditures (CapEx)		 0.45 0.42 0.59 0.46 0.22 0.10 0.32 0.37 0.07 0.09 0.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 10 9.38 13 12 11 13 13 12 12 4.39 7.16
Debt-free Net Working Capital (DFNWC)		 99 101 93 82 72 63 54 44 53 43 30
Net Working Capital (NWC)		 99 101 93 82 72 63 54 44 53 43 30
Net Nonoperating Expense (NNE)		 3.28 2.64 3.33 3.21 2.90 2.51 3.10 3.35 3.54 3.95 4.58
Net Nonoperating Obligations (NNO)		 -104 -95 -80 -69 -61 -51 -42 -27 -18 -19 -3.90
Total Depreciation and Amortization (D&A)		 0.78 0.79 0.81 0.83 0.86 0.87 0.85 0.81 0.80 0.79 0.79
Debt-free, Cash-free Net Working Capital to Revenue		 48.83% 41.64% 56.39% 49.40% 42.73% 44.99% 42.22% 41.23% 39.83% 13.06% 20.82%
Debt-free Net Working Capital to Revenue		 483.69% 450.42% 400.78% 330.21% 275.18% 225.85% 182.78% 144.42% 174.96% 127.08% 87.56%
Net Working Capital to Revenue		 483.69% 450.42% 400.78% 330.21% 275.18% 225.85% 182.78% 144.42% 174.96% 127.08% 87.56%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.31) ($0.26) ($0.31) ($0.29) ($0.26) ($0.22) ($0.26) ($0.27) ($0.26) ($0.26) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 43.08M 43.02M 43.25M 43.62M 43.67M 43.58M 43.99M 44.65M 44.96M 44.68M 45.43M
Adjusted Diluted Earnings per Share		 ($0.31) ($0.26) ($0.31) ($0.29) ($0.26) ($0.22) ($0.26) ($0.27) ($0.26) ($0.26) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 43.08M 43.02M 43.25M 43.62M 43.67M 43.58M 43.99M 44.65M 44.96M 44.68M 45.43M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.40M 42.50M 42.86M 42.91M 43.03M 43.24M 43.83M 44.21M 44.32M 45.46M 46.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -10 -8.53 -9.99 -9.36 -8.43 -7.16 -8.16 -8.50 -7.96 -8.55 -9.70
Normalized NOPAT Margin		 -164.59% -134.63% -178.06% -141.50% -110.83% -87.13% -113.29% -117.10% -101.56% -75.76% -121.17%
Pre Tax Income Margin		 -217.77% -176.17% -237.37% -189.83% -148.74% -117.73% -156.22% -163.14% -146.68% -110.65% -178.29%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -1,098.00 0.00 -975.83 0.00 -29.14 0.00 -21.73
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -766.12 0.00 -680.23 0.00 -20.26 0.00 -15.17
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -1,118.27 0.00 -1,002.42 0.00 -29.32 0.00 -22.34
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -786.39 0.00 -706.81 0.00 -20.44 0.00 -15.79
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Rapid Micro Biosystems (NASDAQ: RPID) continues to grow revenue, but the company is still producing large operating losses and burning cash. Over the last several years, the trend is mixed: sales have generally improved from the 2024 lows, gross margins have become much healthier in recent quarters, and the balance sheet still shows a meaningful cash cushion. However, operating expenses remain far above gross profit, so the business is not yet close to profitability.

Revenue and gross profit trends: Q1 2026 revenue was $8.0 million, up from $7.2 million in Q1 2025 and above the $5.6 million level in Q1 2024. Gross profit in Q1 2026 was only $371,000, but that was a big improvement from the negative gross profit the company posted in early 2024 and late 2024. In other words, the company has made progress on product economics, even though the absolute dollar profit is still very small.

Expense control remains the key problem. In Q1 2026, operating expenses totaled $14.2 million versus just $371,000 of gross profit, leading to an operating loss of $13.9 million. That is slightly worse than Q1 2025 and still indicates the company is spending far more than it generates from sales. SG&A, marketing, and R&D are all still large relative to revenue.

Bottom-line losses persist. Rapid Micro reported a net loss of $14.3 million in Q1 2026, wider than the $11.3 million loss in Q1 2025. Quarterly EPS was negative $0.31, showing the company is still far from breakeven.

Cash flow is weak from operations, but investing activity helped the quarter. Operating cash flow was negative $15.1 million in Q1 2026, worse than the negative $9.1 million in Q1 2025. The company generated positive investing cash flow because it sold more investments than it bought, which helped offset the operating burn. Financing inflow was modest at $247,000.

Liquidity appears adequate for now, but it is declining. At March 31, 2026, the company had $13.8 million in cash and $9.1 million in short-term investments, for about $22.9 million of liquid resources. That is down from roughly $31.3 million at Q1 2025 and well below the much higher liquidity levels seen in 2024. Cash declined by $6.2 million in Q1 2026.

The balance sheet still carries meaningful leverage. Rapid Micro ended Q1 2026 with $41.9 million of liabilities and $20.4 million of common equity. Long-term debt was $19.1 million. The company is not in a severe liquidity crisis based on the numbers provided, but it does not have a lot of room for prolonged operating losses.

  • Revenue improved year over year, with Q1 2026 sales of $8.0 million versus $7.2 million in Q1 2025 and $5.6 million in Q1 2024.
  • Gross profit has improved materially versus the loss-making gross margin periods in 2024.
  • Cash and short-term investments remain meaningful at about $22.9 million as of March 31, 2026.
  • Investments provided cash support in Q1 2026 as the company sold more securities than it purchased.
  • Share count has drifted higher over time, which can dilute existing shareholders if it continues.
  • Debt remains on the balance sheet at roughly $19.1 million, so interest expense will continue to weigh on results.
  • Capital spending is relatively modest, suggesting management is not aggressively expanding the asset base right now.
  • Operating losses remain very large relative to revenue, with Q1 2026 operating loss at $13.9 million.
  • Operating cash burn increased to $15.1 million in Q1 2026.
  • Cash balances are trending lower compared with prior-year periods, limiting flexibility if losses persist.

Bottom line: Rapid Micro Biosystems is showing some encouraging signs on revenue growth and gross profit improvement, but the business still has a long way to go before it reaches sustainable profitability. For investors, the key question is whether the company can keep growing sales while narrowing operating losses fast enough to avoid further balance-sheet pressure.

07/15/26 05:15 PM ETAI Generated. May Contain Errors.

Rapid Micro Biosystems Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Rapid Micro Biosystems' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Rapid Micro Biosystems' net income appears to be on a downward trend, with a most recent value of -$47.12 million in 2025, rising from -$37.08 million in 2020. The previous period was -$46.89 million in 2024. See where experts think Rapid Micro Biosystems is headed by visiting Rapid Micro Biosystems' forecast page.

Rapid Micro Biosystems' total operating income in 2025 was -$47.39 million, based on the following breakdown:
  • Total Gross Profit: $1.05 million
  • Total Operating Expenses: $48.44 million

Over the last 5 years, Rapid Micro Biosystems' total revenue changed from $16.08 million in 2020 to $33.59 million in 2025, a change of 108.9%.

Rapid Micro Biosystems' total liabilities were at $41.65 million at the end of 2025, a 82.5% increase from 2024, and a 7.8% decrease since 2020.

In the past 5 years, Rapid Micro Biosystems' cash and equivalents has ranged from $16.91 million in 2024 to $178.39 million in 2021, and is currently $20.03 million as of their latest financial filing in 2025.

Over the last 5 years, Rapid Micro Biosystems' book value per share changed from -354.19 in 2020 to 0.75 in 2025, a change of -100.2%.


Related Companies

Financial statements for NASDAQ:RPID last updated on 7/15/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel